Mounjaro: SURMOUNT-1, Jastreboff et al., NEJM (2022), 15 mg over 72 weeks (around 17 months).
Wegovy injection: UK product information, section 5.1; STEP 1 (2.4 mg, 68 weeks) and STEP UP (7.2 mg, 72 weeks). Wegovy tablets: UK product information, section 5.1; OASIS 4 (25 mg, 64 weeks).
Foundayo: ATTAIN-1, Wharton et al., NEJM (2025), 36 mg capsule over 72 weeks. The UK product information explains its equivalence to the 17.2 mg film-coated tablet.
Rounded figures use treatment-policy/treatment-regimen analyses, not estimates assuming everyone stays on treatment. The studies involved adults without diabetes; populations, methods and durations differ.